JPRN-UMIN000024333已完成2 期
Phase 2 study of 2nd line dose-escalated nab-Paclitaxel for advanced or recurrent gastric cancer (KGSG1301) - Phase 2 study of 2nd line dose-escalated nab-Paclitaxel
Graduate School of Medical Science, Kumamoto Universit0 个研究点目标入组 45 人开始时间: 2016年10月7日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Severe bone marrow suppression 2)Complicated by infection 3)History of hypersensitivity to ABI, PAC or albumin 4)History of serious hypersensitivity 5)Pregnant or nursing woman 6)Significant abnormal electrocardiogram or heart disease to be clinically relevant 7)Pleural effusion or ascites in need of treatment 8)Brain metastases 9)Active double cancer (synchronous double cancer or metachronous double cancer with a disease-free interval of less than five years; carcinoma in situ judged to be cured by local treatment are not considered to be active double cancers) 10)Peripheral neuropathy which were graded 2 or higher 11)Interstitial pneumonia or pulmonary fibrosis 12)HBs antigen or HCV antibody positive 13)Physician concludes that the patient's participation in this trial is inappropriate
研究者
相似试验
招募中
2 期
Phase 2 study of dose-dense nab-paclitaxel followed by EC as neoadjuvant chemotherapy for HER2-negative breast cancerHER2-negative primary breast cancerJPRN-UMIN000026143Teikyo University School of Medicine50
已完成
不适用
Phase II Study for Efficacy and Safety of nab-paclitaxel for Previously Treated Advanced Non-small Cell Lung Cancerlung cancerJPRN-UMIN000010737Tokyo Metropolitan Cancer and Infection diseases Center Komagome Hospital22
招募中
2 期
Phase 2 study of neoadjuvant tri-weekly Nab-paclitaxel and Trastuzumab followed by FEC(5-FU/epirubicin/cyclophosphamide) in patients for HER2 positive breast cancer.JPRN-UMIN000010579Department of gastroenterologic and breast surgery Kanazawa University,School of Medicine35
招募中
2 期
A phase II neoadjuvant trial of sequential nab-paclitaxel followed by dose dense epirubicine/cyclophosphamide (ddEC) in operable breast cancerbreast cancerJPRN-UMIN000041509Breast Surgery, Yokkaichi Municipal Hospital20
已完成
2 期
A phase II neoadjuvant trial of sequential nab-paclitaxel followed by 5-fluorouracil/epirubicine/cyclophosphamide (FEC) in operable breast cancerbreast cancerJPRN-UMIN000032153Yokkaichi Municipal Hospital50